Dear Innitius Community,
In our last newsletter, we reflected on 2024 and our transition from a single-product focus to a multi-solution platform. This strategic shift has allowed us to expand our impact across four key areas: Threatened Preterm Labor (TPTL), Preterm Labor Prognosis (PTL), Induction of Labor (IOL), and our Science Research Platform. This month, we take a closer look at each area and how Innitius is advancing solutions for women’s healthcare.
Threatened Preterm Labor (TPTL)
TPTL has been a core focus for Innitius since our inception. It remains the leading cause of hospitalization during pregnancy, with a significant economic burden—estimated at €8 billion in the EU and €1.2 billion in the US and EU combined.
Preterm labor occurs before 37 weeks of pregnancy and is characterized by uterine contractions and changes in the cervix. When these clinical signs are absent, a diagnosis of TPTL is considered. However, only 15% of hospitalized TPTL cases result in spontaneous preterm birth within seven days, while 85% do not lead to preterm delivery. Accurately distinguishing true TPTL cases ensures necessary medical intervention while preventing unnecessary hospitalizations, reducing maternal stress, and minimizing healthcare costs.
Preterm Labor Prognosis (PTL)
Approximately 40% of preterm labor cases go undetected during mid-trimester ultrasound scans. This highlights the urgent need for improved diagnostic tools that can predict preterm labor more effectively, ensuring timely interventions for at-risk pregnancies.
By integrating advanced diagnostic technologies like CerviSense, we aim to provide a more reliable approach for identifying preterm labor risks, enabling proactive clinical decisions that can improve maternal and neonatal health outcomes.
Induction of Labor (IOL)
Labor induction is a critical medical intervention used when the health of the mother or fetus is at risk, or when labor fails to progress naturally. However, it remains the number one cause of fetal distress during pregnancy. Shockingly, 20% of labor inductions fail, leading to prolonged fetal distress and unnecessary hospital stays of up to 48 hours.
Failed inductions not only lead to extended hospital stays but also increase the likelihood of emergency interventions. The ability to accurately assess cervical readiness before initiating induction is crucial in preventing these complications.
Science Research Platform
Our Science Research Platform is a groundbreaking initiative aimed at creating the world’s largest cervix consistency database. By leveraging our CerviSense device, we provide researchers and clinicians with insights into cervical softness quantification. This data-driven approach paves the way for advancements in women’s healthcare, fostering innovation in diagnostics and treatment.
The platform enables collaboration between leading obstetricians, researchers, and healthcare institutions, supporting research and the development of innovative approaches to pregnancy care.
The Technology Behind It All: CerviSense
At the heart of our multi-solution platform is CerviSense, a torsional wave probe that quantifies cervical softness. By combining real-time cervical softness data with AI-driven analytics, CerviSense allows healthcare providers to make more informed decisions, improving patient outcomes and reducing unnecessary medical interventions.
Our vision is to continue refining this technology, ensuring that it becomes an indispensable tool in obstetric care worldwide.
At Innitius, our mission remains clear: to develop breakthrough medical devices that enhance patient care through innovative technology. By addressing the most pressing challenges in obstetrics, we are shaping the future of maternal health.
Stay tuned as we continue to drive change in women’s healthcare!